|
1
|
Folkman J: The role of angiogenesis in
tumor growth. Semin Cancer Biol. 3:65–71. 1992.PubMed/NCBI
|
|
2
|
Blumberg N: Tumor angiogenesis factor.
Speculations on an approach to cancer chemotherapy. Yale J Biol
Med. 47:71–81. 1974.PubMed/NCBI
|
|
3
|
Milowsky MI, Nanus DM, Kostakoglu L,
Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS and Bander NH:
Vascular targeted therapy with anti-prostate-specific membrane
antigen monoclonal antibody J591 in advanced solid tumors. J Clin
Oncol. 25:540–547. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bose D, Meric-Bernstam F, Hofstetter W,
Reardon DA, Flaherty KT and Ellis LM: Vascular endothelial growth
factor targeted therapy in the perioperative setting: Implications
for patient care. Lancet Oncol. 11:373–382. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kessler T, Bieker R, Padró T, Schwöppe C,
Persigehl T, Bremer C, Kreuter M, Berdel WE and Mesters RM:
Inhibition of tumor growth by RGD peptide-directed delivery of
truncated tissue factor to the tumor vasculature. Clin Cancer Res.
11:6317–6324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schwöppe C, Kessler T, Persigehl T,
Liersch R, Hintelmann H, Dreischalück J, Ring J, Bremer C, Heindel
W, Mesters RM and Berdel WE: Tissue-factor fusion proteins induce
occlusion of tumor vessels. Thromb Res. 125(Suppl 2): S143–S150.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Furie B and Furie BC: The molecular basis
of coagulation. Cell. 53:505–518. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Persigehl T, Ring J, Bremer C, Heindel W,
Holtmeier R, Stypmann J, Claesener M, Hermann S, Schäfers M, Zerbst
C, et al: Non-invasive monitoring of tumor-vessel infarction by
retargeted truncated tissue factor tTF-NGR using multi-modal
imaging. Angiogenesis. 17:235–246. 2014. View Article : Google Scholar
|
|
9
|
Alessi P, Ebbinghaus C and Neri D:
Molecular targeting of angiogenesis. Biochim Biophys Acta.
1654:39–49. 2004.PubMed/NCBI
|
|
10
|
Archer R, Wakabayashi M, Sevilla R,
Summers S, King S and Aimes R: Targeting truncated tissue factor
with tumor vascula-ture specific monoclonal antibodies: Developing
coaguligands as cancer therapeutics. Cancer Res. 67:14–18.
2007.
|
|
11
|
Kessler T, Schwöppe C, Liersch R,
Schliemann C, Hintelmann H, Bieker R, Berdel WE and Mesters RM:
Generation of fusion proteins for selective occlusion of tumor
vessels. Curr Drug Discov Technol. 5:1–8. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Soker S, Takashima S, Miao HQ, Neufeld G
and Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor
cells as an isoform-specific receptor for vascular endothelial
growth factor. Cell. 92:735–745. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wise LM, Veikkola T, Mercer AA, Savory LJ,
Fleming SB, Caesar C, Vitali A, Makinen T, Alitalo K and Stacker
SA: Vascular endothelial growth factor (VEGF)-like protein from orf
virus NZ2 binds to VEGFR2 and neuropilin-1. Proc Natl Acad Sci USA.
96:3071–3076. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gagnon ML, Bielenberg DR, Gechtman Z, Miao
HQ, Takashima S, Soker S and Klagsbrun M: Identification of a
natural soluble neuropilin-1 that binds vascular endothelial growth
factor: In vivo expression and antitumor activity. Proc Natl Acad
Sci USA. 97:2573–2578. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bergé M, Allanic D, Bonnin P, de Montrion
C, Richard J, Suc M, Boivin JF, Contrerès JO, Lockhart BP, Pocard
M, et al: Neuropilin-1 is upregulated in hepatocellular carcinoma
and contributes to tumour growth and vascular remodelling. J
Hepatol. 55:866–875. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seifi-Alan M, Shams R, Bandehpour M,
Mirfakhraie R and Ghafouri-Fard S: Neuropilin-1 expression is
associated with lymph node metastasis in breast cancer tissues.
Cancer Manag Res. 10:1969–1974. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang X, Molema G, King S, Watkins L,
Edgington TS and Thorpe PE: Tumor infarction in mice by
antibody-directed targeting of tissue factor to tumor vasculature.
Science. 275:547–550. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Thorpe PE: Vascular targeting agents as
cancer therapeutics. Clin Cancer Res. 10:415–427. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu P, Yan J, Sharifi J, Bai T, Khawli LA
and Epstein AL: Comparison of three different targeted tissue
factor fusion proteins for inducing tumor vessel thrombosis. Cancer
Res. 3:5046–5053. 2003.
|
|
20
|
Saga T, Weinstein JN, Jeong JM, Heya T,
Lee JT, Le N, Paik CH, Sung C and Neumann RD: Two-Step targeting of
experimental lung metastases with biotinylated antibody and
radiolabeled streptavidin. Cancer Res. 54:2160–2165.
1994.PubMed/NCBI
|
|
21
|
Zhang M, Sakahara H, Yao Z, Saga T,
Nakamoto Y, Sato N, Nakada H, Yamashina I and Konishi J:
Intravenous avidin chase improved localization of radiolabeled
streptavidin in intraperito-neal xenograft pretargeted with
biotinylated antibody. Nucl Med Biol. 24:61–64. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sakahara H and Saga T: Avidin-biotin
system for delivery of diagnostic agents. Adv Drug Deliv Rev.
37:89–101. 1999. View Article : Google Scholar
|
|
23
|
Liu X, Yang Q, Nakamura C and Miyake J:
Avidin-biotin- immobilized liposome column for chromatographic
fluorescence on-line analysis of solute-membrane interactions. J
Chromatogr B Biomed Sci Appl. 750:51–60. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Medina LA, Calixto SM, Klipper R, Phillips
WT and Goins B: Avidin/biotin-liposome system injected in the
pleural space for drug delivery to mediastinal lymph nodes. J Pharm
Sci. 93:2595–2608. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nobs L, Buchegger F, Gurny R and Allémann
E: Biodegradable nanoparticles for direct or two-step tumor
immunotargeting. Bioconjug Chem. 17:139–145. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kheirolomoom A, Dayton PA, Lum AF, Little
E, Paoli EE, Zheng H and Ferrara KW: Acoustically-active
microbubbles conjugated to liposomes: Characterization of a
proposed drug delivery vehicle. J Control Release. 118:275–284.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Goldenberg DM, Sharkey RM, Paganelli G,
Barbet J and Chatal JF: Antibody pretargeting advances cancer
radioimmu-nodetection and radioimmunotherapy. J Clin Oncol.
24:823–834. 2006. View Article : Google Scholar
|
|
28
|
Urbano N, Papi S, Ginanneschi M, De Santis
R, Pace S, Lindstedt R, Ferrari L, Choi S, Paganelli G and Chinol
M: Evaluation of a new biotin-DOTA conjugate for pretargeted
antibody-guided radioimmunotherapy (PAGRIT). Eur J Nucl Med Mol
Imaging. 34:68–77. 2007. View Article : Google Scholar
|
|
29
|
Zeng F, Luo F, Lv S, Zhang H, Cao C, Chen
X, Wang S, Li Z, Wang X, Dou X, et al: A monoclonal antibody
targeting neuropilin-1 inhibits adhesion of MCF7 breast cancer
cells to fibronectin by suppressing the FAK/p130cas signaling
pathway. Anticancer Drugs. 25:663–672. 2014.PubMed/NCBI
|
|
30
|
Chen F, Nielsen S and Zenobi R:
Understanding chemical reactivity for homo- and heterobifunctional
protein cross-linking agents. J Mass Spectrom. 48:807–812. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nwe K, Milenic DE, Ray GL, Kim YS and
Brechbiel MW: Preparation of cystamine core dendrimer and
antibody-dendrimer conjugates for MRI angiography. Mol Pharm.
9:374–381. 2012. View Article : Google Scholar
|
|
32
|
Neerman MF, Zhang W, Parrish AR and
Simanek EE: In vitro and in vivo evaluation of a melamine dendrimer
as a vehicle for drug delivery. Int J Pharm. 281:129–132. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chan EC and Ho PC: Preparation and
characterization of immunogens for antibody production against
metanephrine and normetanephrine. J Immunol Methods. 266:143–154.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu ZC, Shen HX, Chen C, Ma L, Li WZ, Wang
L and Geng ZM: Neuropilin-1 promotes primary liver cancer
progression by potentiating the activity of hepatic stellate cells.
Oncol Lett. 15:2245–2251. 2018.PubMed/NCBI
|
|
35
|
Wang L, Zeng H, Wang P, Soker S and
Mukhopadhyay D: Neuropilin-1-mediated vascular permeability
Factor/Vascular endothelial growth Factor-dependent endothelial
cell migration. J Biol Chem. 278:48848–48860. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen X, Lv H, Ye M, Wang S, Ni E, Zeng F,
Cao C, Luo F and Yan J: Novel superparamagnetic iron oxide
nanoparticles for tumor embolization application: Preparation,
characterization and double targeting. Int J Pharm. 426:248–255.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hylarides MD, Mallett RW and Meyer DL: A
robust method for the preparation and purification of
Antibody/streptavidin conjugates. Bioconjug Chem. 12:421–427. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liao MY, Kuo MY, Lu TY, Wang YP and Wu HC:
Generation of an anti-EpCAM antibody and epigenetic regulation of
EpCAM in colorectal cancer. Int J Oncol. 46:1788–1800. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gottstein C, Wels W, Ober B and Thorpe PE:
Generation and characterization of recombinant vascular targeting
agents from hybridoma cell lines. Biotechniques. 30:190–194. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu Z, Rao B, Chen S and Duanmu J:
Selective and effective killing of angiogenic vascular endothelial
cells and cancer cells by targeting tissue factor using a factor
VII-targeted photodynamic therapy for breast cancer. Breast Cancer
Res Treat. 126:589–600. 2011. View Article : Google Scholar
|
|
41
|
Rades D, Fehlauer F, Bajrovic A, Mahlmann
B, Richter E and Alberti W: Serious adverse effects of amifostine
during radiotherapy in head and neck cancer patients. Radiother
Oncol. 70:261–264. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Monsuez JJ, Charniot JC, Vignat N and
Artigou JY: Cardiac side-effects of cancer chemotherapy. Int J
Cardiol. 144:3–15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dienst A, Grunow A, Unruh M, Rabausch B,
Nör JE, Fries JW and Gottstein C: Specific occlusion of murine and
human tumor vasculature by VCAM-1-targeted recombinant fusion
proteins. J Natl Cancer Inst. 97:733–747. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bieker R, Kessler T, Schwöppe C, Padró T,
Persigehl T, Bremer C, Dreischalück J, Kolkmeyer A, Heindel W,
Mesters RM and Berdel WE: Infarction of tumor vessels by
NGR-peptide-directed targeting of tissue factor: Experimental
results and first-in-man experience. Blood. 113:5019–5027. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lv S, Ye M, Wang X, Chen X, Dou X, Dai Y,
Dai Y, Zeng F, Luo L, Wang C, et al: A recombined fusion protein
SP5.2/tTF induce thrombosis in tumor blood vessel. Neoplasma.
62:531–540. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schmidt LH, Stucke-Ring J, Brand C,
Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M,
Görlich D, et al: CD13 as target for tissue factor induced tumor
vascular infarction in small cell lung cancer. Lung Cancer.
113:121–127. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pan Q, Chanthery Y, Liang WC, Stawicki S,
Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco G, et al:
Blocking neuro-pilin-1 function has an additive effect with
anti-VEGF to inhibit tumor growth. Cancer Cell. 11:53–67. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Grandclement C and Borg C: Neuropilins: A
new target for cancer therapy. Cancers (Basel). 3. pp. 1899–1928.
2011, View Article : Google Scholar
|
